GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Topiramate Bioequivalence Study Brazil - Fast
Phase 1
Completed
- Conditions
- Epilepsy, Tonic-Clonic
- Interventions
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT01439438
- Locations
- 🇧🇷
GSK Investigational Site, Campinas, São Paulo, Brazil
A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise
Phase 3
Withdrawn
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01435902
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 351
- Registration Number
- NCT01436110
- Locations
- 🇷🇺
GSK Investigational Site, St. Petersburg, Russian Federation
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
Completed
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Drug: Early combination therapyDrug: Delayed combination therapy
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 13551
- Registration Number
- NCT01435954
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 248
- Registration Number
- NCT01436071
- Locations
- 🇷🇺
GSK Investigational Site, Yaroslavl, Russian Federation
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
Completed
- Conditions
- Migraine Disorders
- Interventions
- Drug: Non-steroidal anti-inflammatory drug (NSAID)Drug: Triptan
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 11249
- Registration Number
- NCT01435941
Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT01435915
- Locations
- 🇨🇳
GSK Investigational Site, Beijing, China
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
Phase 1
Terminated
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Other: Saline placebo
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3
- Registration Number
- NCT01435993
- Locations
- 🇳🇴
GSK Investigational Site, Lørenskog, Norway
Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™
Completed
- Conditions
- Infections, Rotavirus
- Interventions
- Other: Data collection
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01435967
- Locations
- 🇧🇪
GSK Investigational Site, Yvoir, Belgium
Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Early maintenance treatmentDrug: Delayed Maintenance treatment
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3806
- Registration Number
- NCT01431911